Stuart Roberts is an investment professional who did Australian equity research from the late 1990s until early 2015 and again from mid-2016. For a lot of the time he has worked as an analyst I focused on healthcare and biotechnology, and the Life Sciences has become a passion of his. Roberts's forte is making complex, technology-based investment ideas easy to understand. In January 2015 he joined his first biotechnology company, a cancer immunotherapy play called Prima Biomed (Nasdaq: PBMD) and had a great time with them until November 2015. From January until May 2016 he took care of investor relations for another cancer immunotherapy company, Imugene (ASX: IMU). In June 2016 he returned to the equities analyst game with the founding of NDF Research. Two years later in June 2018 I teamed up with Marc Kennis to found Pitt Street Research with the aim of providing issuer-sponsored equity research to the entire spectrum of ASX-listed companies. In 2020 Pitt Street Research started Stocks Down Under (stocksdownunder.com).
EN 
中文
日本語
Australia
Brunei
Germany
Hong Kong
India
Indonesia
Israel
Malaysia
Nepal
New Zealand
Philippines
Singapore
Taiwan
Thailand
United Arab Emirates
United States
Vietnam
More Countries